Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?

August 30, 2017 - By Migdalia James

 Were Analysts Bullish Argos Therapeutics Inc (NASDAQ:ARGS) This Week?
Investors sentiment increased to 2.7 in 2016 Q4. Its up 0.14, from 2.56 in 2016Q3. It increased, as 2 investors sold Argos Therapeutics Inc shares while 8 reduced holdings. 8 funds opened positions while 19 raised stakes. 7.25 million shares or 21.41% more from 5.97 million shares in 2016Q3 were reported.
State Street Corp reported 177,494 shares or 0% of all its holdings. 153,065 were accumulated by Geode Mgmt. Altrinsic Glob Advsr invested in 172,505 shares or 0.03% of the stock. Morgan Stanley accumulated 51,285 shares. Wells Fargo Communication Mn stated it has 11,132 shares. Goldman Sachs Grp holds 13,399 shares or 0% of its portfolio. Nationwide Fund Advsrs accumulated 11,678 shares or 0% of the stock. Ny State Common Retirement Fund holds 0% or 1,500 shares in its portfolio. Blackrock Institutional Na holds 149,302 shares. New Jersey-based Blackrock Investment Ltd Liability Company has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Barclays Public Ltd Limited Liability Company, a United Kingdom-based fund reported 357 shares. New York-based Bnp Paribas Arbitrage Sa has invested 0% in Argos Therapeutics Inc (NASDAQ:ARGS). Millennium Management Limited Com holds 0% or 143,113 shares. Tower Research Cap Limited Liability Corporation (Trc) holds 0% or 300 shares in its portfolio. Wasatch holds 3.25 million shares.

Argos Therapeutics Inc (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Argos Therapeutics had 5 analyst reports since November 16, 2015 according to SRatingsIntel. As per Thursday, August 11, the company rating was maintained by FBR Capital. As per Wednesday, March 9, the company rating was maintained by JMP Securities. Roth Capital maintained the shares of ARGS in report on Tuesday, April 19 with “Buy” rating. Needham maintained Argos Therapeutics Inc (NASDAQ:ARGS) on Tuesday, November 17 with “Buy” rating. FBR Capital maintained Argos Therapeutics Inc (NASDAQ:ARGS) rating on Monday, November 16. FBR Capital has “Outperform” rating and $17 target. Below is a list of Argos Therapeutics Inc (NASDAQ:ARGS) latest ratings and price target changes.

It closed at $0.2 lastly. It is down 92.57% since August 30, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc. is an immuno-oncology company. The company has market cap of $10.99 million. The Firm is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. It currently has negative earnings. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

More recent Argos Therapeutics Inc (NASDAQ:ARGS) news were published by: Reuters.com which released: “BRIEF-Argos Therapeutics files for possible resale up to 18.9 mln shares” on August 16, 2017. Also Globenewswire.com published the news titled: “Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be …” on August 21, 2017. Globenewswire.com‘s news article titled: “Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent …” with publication date: August 09, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.